The Journal of Immunology, Vol 147, Issue 4 1352-1359, Copyright © 1991 by American Association of Immunologists

ARTICLES

Reduced immunogenicity and improved pharmacokinetics of humanized anti- Tac in cynomolgus monkeys

J Hakimi, R Chizzonite, DR Luke, PC Familletti, P Bailon, JA Kondas, RS Pilson, P Lin, DV Weber and C Spence
Department of Immunopharmacology, Hoffman-La Roche, Inc., Nutley, NJ 07110.

The anti-Tac mAb has been shown to bind to the p55 chain of the IL-2R, block IL-2 binding and inhibit T cell proliferation. A humanized form of anti-Tac (HAT) has been constructed that retains the binding properties of murine anti-Tac (MAT). These two mAb were evaluated in cynomolgus monkeys to compare relative immunogenicity and pharmacokinetic properties. Monkeys treated with HAT daily for 14 days exhibited anti-HAT antibody titers which were 5- to 10-fold lower than their MAT-treated counterparts and these antibodies developed later than in the MAT-treated monkeys. Two of four monkeys receiving a single injection of MAT developed anti-MAT antibodies, whereas none of four monkeys developed antibodies after a single treatment with HAT. In monkeys injected with either HAT or MAT daily for 14 days, the anti- antibody titers induced were inversely related to the amount of anti- Tac administered. Antibodies that developed against MAT were both anti- isotypic and anti-idiotypic, whereas those developed against HAT appeared to be predominantly anti-idiotypic. The pharmacokinetic properties, that is the half-life and area under the curve values, of HAT were also significantly different from those of MAT. The area under the curve values for HAT in naive monkeys were approximately twofold more than those for MAT, and the mean serum half-life of HAT was 214 h, approximately four- to fivefold more than MAT. These pharmacokinetic values were reduced in monkeys previously sensitized with HAT or MAT suggesting that the presence of anti-antibodies altered these parameters.

This article has been cited by other articles:

				G. Dancey, J. Violet, A. Malaroda, A. J. Green, S. K. Sharma, R. Francis, S. Othman, S. Parker, J. Buscombe, N. Griffin, et al. A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma Clin. Cancer Res., December 15, 2009; 15(24): 7701 - 7710. [Abstract] [Full Text] [PDF]

				N. F. Landolfi, A. B. Thakur, H. Fu, M. Vasquez, C. Queen, and N. Tsurushita The Integrity of the Ball-and-Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody J. Immunol., February 1, 2001; 166(3): 1748 - 1754. [Abstract] [Full Text] [PDF]

				A. Beniaminovitz, S. Itescu, K. Lietz, M. Donovan, E. M. Burke, B. D. Groff, N. Edwards, and D. M. Mancini Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody N. Engl. J. Med., March 2, 2000; 342(9): 613 - 619. [Abstract] [Full Text] [PDF]

				Y. S. Lin, C. Nguyen, J.-L. Mendoza, E. Escandon, D. Fei, Y. G. Meng, and N. B. Modi Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 371 - 378. [Abstract] [Full Text]

				F. Vincenti, R. Kirkman, S. Light, G. Bumgardner, M. Pescovitz, P. Halloran, J. Neylan, A. Wilkinson, H. Ekberg, R. Gaston, et al. Interleukin-2-Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation N. Engl. J. Med., January 15, 1998; 338(3): 161 - 165. [Abstract] [Full Text] [PDF]

				M. Baca, L. G. Presta, S. J. O'Connor, and J. A. Wells Antibody Humanization Using Monovalent Phage Display J. Biol. Chem., April 18, 1997; 272(16): 10678 - 10684. [Abstract] [Full Text] [PDF]